Skip to content

US · IRIX · MEDICAL - DEVICES

IRIDEX Corporation (IRIX) intrinsic value and stock valuation

$0.44as of 2026-11-21 · Mkt cap 14.61M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

IRIDEX Corporation DCF and intrinsic value

InvestorsCraft values IRIX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IRIX’s statements →

IRIDEX Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Mountain View, CA 94043 iridex.com

How the business is doing

Fiscal 2011–2026, USD

Revenue
$52.7M+7.7% 5y CAGRd
20112026
Net income
-$-4.44M
20112026
Free cash flow
-$-2.26M
20112026
Total equity
$4.92M-22.3% 5y CAGRd
20112026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2026, USD
20262024202320222021
Revenue$52.7M$48.7M$51.9M$57M$53.9M
Operating income-$-2.57M-$-8.3M-$-10.01M-$-7.54M-$-7.53M
Net income-$-4.44M-$-8.91M-$-9.57M-$-7.55M-$-5.22M
EPSd-$-258.29K-$-541.97K-$-593.3K-$-473.65K-$-338.52K
Operating cash flow-$-2.12M-$-7.29M-$-6.75M-$-9.52M$8.22M
Capital expenditure-$-140K-$-10K-$-110K-$-290K-$-210K
Free cash flow-$-2.26M-$-7.3M-$-6.85M-$-9.8M$8M
Total assets$29.2M$29.1M$34.4M$42.3M$48.7M
Total debt$4.53M$4.64M$2.75M$1.77M$2.66M
Net debt-$-1.5M$2.26M-$-4.29M-$-12.15M-$-21.2M
Total equity$4.92M$2.1M$9.52M$17.2M$23.3M
Cash and short-term investments$6.03M$2.39M$7.03M$13.9M$23.9M
Income statement
20262024202320222021
Revenue$52.7M$48.7M$51.9M$57M$53.9M
Cost of revenue$33.4M$29.2M$30.1M$31.6M$31.1M
Gross profit$19.3M$19.5M$21.8M$25.4M$22.8M
Research and development expenses$3.67M$5.45M$6.83M$7.17M$6.87M
Selling, general and administrative expenses$18.1M$22.4M$25M$25.7M$23.5M
Other expenses$80K$0.00$0.00$0.00$0.00
Operating expenses$21.9M$27.8M$31.8M$32.9M$30.4M
Cost and expenses$55.3M$57M$61.9M$64.5M$61.4M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.55M$1.42M$2.03M$1.38M$800K
Ebitda-$-2.83M-$-7.42M-$-7.45M-$-6.1M-$-4.38M
Operating income-$-2.57M-$-8.3M-$-10.01M-$-7.54M-$-7.53M
Total other income/expenses, net-$-1.81M-$-540K$530K$60K$2.35M
Income before tax-$-4.38M-$-8.84M-$-9.48M-$-7.48M-$-5.18M
Income tax expense$60K$70K$90K$70K$40K
Net income-$-4.44M-$-8.91M-$-9.57M-$-7.55M-$-5.22M
Weighted average shares outstanding$17.2M$16.4M$16.1M$15.9M$15.4M
Weighted average diluted shares outstanding$17.2M$16.4M$16.1M$15.9M$15.4M
Balance sheet
20262024202320222021
Cash and short-term investments$6.03M$2.39M$7.03M$13.9M$23.9M
Net receivables$9.54M$8.39M$9.65M$9.77M$9.72M
Inventory$7.88M$10.8M$9.91M$10.6M$7.61M
Total current assets$25.3M$23.6M$27.5M$35.8M$42.3M
Property, plant and equipment, net$830K$1.91M$2.98M$2.13M$2.99M
Goodwill and intangible assets$1.95M$2.27M$2.61M$2.94M$3.17M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.9M$5.57M$6.99M$6.52M$6.43M
Total assets$29.2M$29.1M$34.4M$42.3M$48.7M
Accounts payable$5.38M$6.99M$4.5M$3.86M$2.77M
Short-term debt$700K$2.83M$990K$1.04M$930K
Deferred revenue$3.68M$3.49M$3.33M$3.38M$3.45M
Total current liabilities$13.2M$16.6M$13M$12.5M$12.7M
Long-term debt$3.83M$1.81M$1.75M$730K$1.73M
Deferred revenue, non-current$6.8M$8.35M$10M$11.7M$10.9M
Total non-current liabilities$11M$10.5M$11.9M$12.6M$12.7M
Capital lease obligations$800K$1.91M$2.75M$1.77M$2.66M
Total liabilities$24.2M$27M$24.9M$25.1M$25.4M
Common stock$170K$170K$170K$170K$170K
Retained earnings-$-92.45M-$-88.01M-$-79.04M-$-69.72M-$-62.17M
Accumulated other comprehensive income (loss)-$-10K$50K-$-50K-$-20K$40K
Total equity$4.92M$2.1M$9.52M$17.2M$23.3M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$4.53M$4.64M$2.75M$1.77M$2.66M
Net debt-$-1.5M$2.26M-$-4.29M-$-12.15M-$-21.2M
Cash flow statement
20262024202320222021
Net income-$-4.44M-$-8.91M-$-9.57M-$-7.55M-$-5.22M
Depreciation and amortization$1.55M$1.42M$2.03M$1.38M$1.71M
Stock-based compensation$780K$1.24M$1.65M$1.62M$1.63M
Change in working capital-$-2.38M-$-1.37M-$-860K-$-5.16M$12.6M
Accounts receivable-$-1.15M$1.26M$360K-$-240K-$-2.47M
Inventory$2.12M-$-910K$640K-$-3.02M$270K
Accounts payable-$-1.95M$2.49M$640K$1.09M$1.62M
Net cash provided by operating activities-$-2.12M-$-7.29M-$-6.75M-$-9.52M$8.22M
Investments in property, plant and equipment-$-140K-$-10K-$-110K-$-290K-$-210K
Acquisitions, net$0.00$0.00$0.00$0.00-$-5.34M
Net cash used for investing activities-$-140K-$-10K-$-110K-$-290K-$-5.56M
Common stock issued$6M$3.37M$80K$20K$9.88M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$5.96M$2.6M-$-10K-$-70K$9.47M
Net change in cash$3.64M-$-4.65M-$-6.89M-$-9.93M$12.2M
Cash at end of period$6.03M$2.39M$7.03M$13.9M$23.9M
Operating cash flow-$-2.12M-$-7.29M-$-6.75M-$-9.52M$8.22M
Capital expenditure-$-140K-$-10K-$-110K-$-290K-$-210K
Free cash flow-$-2.26M-$-7.3M-$-6.85M-$-9.8M$8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About IRIDEX Corporation

        IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.

        CEO
        Patrick Mercer
        Employees
        93
        Beta
        0.64

        Explore

        Frequently asked questions

        What is the intrinsic value of IRIDEX Corporation (IRIX)?

        InvestorsCraft does not currently publish an intrinsic value for IRIX. How the IC value is calculated.

        Is IRIX undervalued?

        InvestorsCraft does not publish an undervaluation signal for IRIX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.